These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 32318950)

  • 1. Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study.
    Comi G; Pozzilli C; Morra VB; Bertolotto A; Sangalli F; Prosperini L; Carotenuto A; Iaffaldano P; Capobianco M; Colombo D; Nica M; Rizzoli S; Trojano M
    Neurol Sci; 2020 Oct; 41(10):2843-2851. PubMed ID: 32318950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The real-world effectiveness of natalizumab and fingolimod in relapsing-remitting multiple sclerosis. An Italian multicentre study.
    Curti E; Tsantes E; Baldi E; Caniatti LM; Ferraro D; Sola P; Granella F
    Mult Scler Relat Disord; 2019 Aug; 33():146-152. PubMed ID: 31200271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom.
    Spelman T; Herring WL; Acosta C; Hyde R; Jokubaitis VG; Pucci E; Lugaresi A; Laureys G; Havrdova EK; Horakova D; Izquierdo G; Eichau S; Ozakbas S; Alroughani R; Kalincik T; Duquette P; Girard M; Petersen T; Patti F; Csepany T; Granella F; Grand'Maison F; Ferraro D; Karabudak R; Jose Sa M; Trojano M; van Pesch V; Van Wijmeersch B; Cartechini E; McCombe P; Gerlach O; Spitaleri D; Rozsa C; Hodgkinson S; Bergamaschi R; Gouider R; Soysal A; Castillo-Triviño ; Prevost J; Garber J; de Gans K; Ampapa R; Simo M; Sanchez-Menoyo JL; Iuliano G; Sas A; van der Walt A; John N; Gray O; Hughes S; De Luca G; Onofrj M; Buzzard K; Skibina O; Terzi M; Slee M; Solaro C; Oreja-Guevara ; Ramo-Tello C; Fragoso Y; Shaygannejad V; Moore F; Rajda C; Aguera Morales E; Butzkueven H
    J Med Econ; 2024; 27(1):109-125. PubMed ID: 38085684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
    Baroncini D; Ghezzi A; Annovazzi PO; Colombo B; Martinelli V; Minonzio G; Moiola L; Rodegher M; Zaffaroni M; Comi G
    Mult Scler; 2016 Sep; 22(10):1315-26. PubMed ID: 27230789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis.
    Boz C; Ozakbas S; Terzi M; Karabudak R; Sevim S; Turkoglu R; Soysal A; Balcı BP; Efendi H; Turan ÖF; Yüceyar N; Yetkin MF; Karahan SZ; Demirkıran M; Guler S; Agan K; Kıylıoğlu N; Baba C; Tuncer A; Köseoğlu M
    Neurol Sci; 2023 Jun; 44(6):2121-2129. PubMed ID: 36689010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world retrospective study of effectiveness and safety of FINgOlimod in relapsing remitting multiple sclerosis in the Middle East and North Africa (FINOMENA).
    Alroughani R; AlKawi Z; Hassan A; Al Otaibi H; Mujtaba A; Al Atat R; Riachi N; Akkawi N; Koussa S; Inshasi J; Alsaadi T; Ahmed SF; Al-Aasmi A; Zakaria M; El Fadally H
    Clin Neurol Neurosurg; 2021 Apr; 203():106576. PubMed ID: 33714799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study.
    Barrero F; Mallada-Frechin J; Martínez-Ginés ML; Marzo ME; Meca-Lallana V; Izquierdo G; Ara JR; Oreja-Guevara C; Meca-Lallana J; Forero L; Sánchez-Vera I; Moreno MJ;
    PLoS One; 2020; 15(4):e0230846. PubMed ID: 32240213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years.
    Guerra T; Caputo F; Orlando B; Paolicelli D; Trojano M; Iaffaldano P
    Neurol Sci; 2021 Nov; 42(11):4647-4655. PubMed ID: 33677753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fingolimod versus natalizumab in patients with relapsing remitting multiple sclerosis: a cost-effectiveness and cost-utility study in Iran.
    Rezaee M; Izadi S; Keshavarz K; Borhanihaghighi A; Ravangard R
    J Med Econ; 2019 Apr; 22(4):297-305. PubMed ID: 30561242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
    Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
    Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effectiveness of fingolimod in a Portuguese real-world population.
    Correia I; Batista S; Marques IB; Sousa M; Ferreira R; Nunes C; Macário MC; Sousa L
    Mult Scler Relat Disord; 2016 Mar; 6():41-48. PubMed ID: 27063621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.
    Lorscheider J; Benkert P; Lienert C; Hänni P; Derfuss T; Kuhle J; Kappos L; Yaldizli Ö
    Mult Scler; 2018 May; 24(6):777-785. PubMed ID: 29685071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fingolimod for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia.
    Algahtani H; Shirah B; Al Malik Y; Meftah I
    Clin Neuropharmacol; 2020; 43(2):35-38. PubMed ID: 32106137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts.
    Sharmin S; Lefort M; Andersen JB; Leray E; Horakova D; Havrdova EK; Alroughani R; Izquierdo G; Ozakbas S; Patti F; Onofrj M; Lugaresi A; Terzi M; Grammond P; Grand'Maison F; Yamout B; Prat A; Girard M; Duquette P; Boz C; Trojano M; McCombe P; Slee M; Lechner-Scott J; Turkoglu R; Sola P; Ferraro D; Granella F; Prevost J; Maimone D; Skibina O; Buzzard K; Van der Walt A; Van Wijmeersch B; Csepany T; Spitaleri D; Vucic S; Casey R; Debouverie M; Edan G; Ciron J; Ruet A; De Sèze J; Maillart E; Zephir H; Labauge P; Defer G; Lebrun-Frénay C; Moreau T; Berger E; Clavelou P; Pelletier J; Stankoff B; Gout O; Thouvenot E; Heinzlef O; Al-Khedr A; Bourre B; Casez O; Cabre P; Montcuquet A; Wahab A; Camdessanché JP; Maurousset A; Patry I; Hankiewicz K; Pottier C; Maubeuge N; Labeyrie C; Nifle C; Laplaud D; Koch-Henriksen N; Sellebjerg FT; Soerensen PS; Pfleger CC; Rasmussen PV; Jensen MB; Frederiksen JL; Bramow S; Mathiesen HK; Schreiber KI; Magyari M; Vukusic S; Butzkueven H; Kalincik T;
    CNS Drugs; 2021 Nov; 35(11):1217-1232. PubMed ID: 34536228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A longitudinal real-life comparison study of natalizumab and fingolimod.
    Lanzillo R; Carotenuto A; Moccia M; Saccà F; Russo CV; Massarelli M; De Rosa A; Brescia Morra V
    Acta Neurol Scand; 2017 Sep; 136(3):217-222. PubMed ID: 27976804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden.
    O'Day K; Meyer K; Stafkey-Mailey D; Watson C
    J Med Econ; 2015 Apr; 18(4):295-302. PubMed ID: 25422991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second-line therapy with fingolimod for relapsing-remitting multiple sclerosis in clinical practice: the effect of previous exposure to natalizumab.
    Bianco A; Patanella AK; Nociti V; Marti A; Frisullo G; Plantone D; De Fino C; Fetta A; Batocchi AP; Rossini PM; Mirabella M
    Eur Neurol; 2015; 73(1-2):57-65. PubMed ID: 25402749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A two-years real-word study with fingolimod: early predictors of efficacy and an association between EBNA-1 IgG titers and multiple sclerosis progression.
    Dominguez-Mozo MI; Galán V; Ramió-Torrentà L; Quiroga A; Quintana E; Villar LM; Costa-Frossard L; Fernández-Velasco JI; Villarrubia N; Garcia-Martinez MA; Arroyo R; Alvarez-Lafuente R
    Front Immunol; 2024; 15():1384411. PubMed ID: 38911861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study.
    Meca-Lallana J; Ayuso T; Martínez-Yelamos S; Durán C; Contreras Martín Y; Herrera Navarro N; Pérez Sempere A; Álvarez-Cermeño JC; Millán Pascual J; Meca-Lallana V; Romero Sevilla R; Ricart J
    Eur Neurol; 2020; 83(1):25-33. PubMed ID: 32187609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of switching from fingolimod and natalizumab to rituximab in patients with relapsing remitting multiple sclerosis.
    Fakih AU; Sahraian MA; Paybast S; Naser Moghadasi A
    Mult Scler Relat Disord; 2023 Mar; 71():104564. PubMed ID: 36863084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.